Viking Therapeutics

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The firm's clinical program, VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in the development of VK2809 and VK0214. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Viking Therapeutics reports solid financials and advances in clinical programs

Viking Therapeutics showcased a strong financial position and progress in clinical programs for various disorders
Challenges include observing full efficacy in short studies and balancing efficacy with safety in dose decisions
Opportunities lie in achieving target efficacy ranges, optimizing dosing based on data, and releasing comprehensive study results

Viking Therapeutics reports Q1 progress and financial stability post-offering

Viking Therapeutics showcased progress in clinical programs and financial stability post-public offering.
Analyst inquiries focused on tolerability, dosing, and expectations for top-line results of key compounds.
Challenges include managing expenses, PK/PD profile comparisons, and uncertainties in enrollment for upcoming studies.
Opportunities lie in pipeline expansions, confidence in oral formulation data, and potential combination studies for future growth.

Viking Therapeutics excels in clinical trials and financial stability

Viking Therapeutics delivered strong clinical and financial performance in Q2 2023, positioning itself well in the NASH and obesity markets.
The company's methodical approach to clinical trials and focus on internal development underscore a strategic and disciplined growth strategy.
While facing financial challenges and operational complexities, Viking has opportunities to leverage positive trial results and cash reserves for future growth.
Overall, Viking's Q2 performance reflects a balanced pursuit of innovation, financial prudence, and strategic advancement in its pipeline.

Viking Therapeutics reports robust Q3 performance and eyes combination therapies

Viking Therapeutics showcased strong clinical data and financial stability in Q3 2023, with key trials progressing as planned.
While facing challenges like limited MRI data and formulation complexities, the company's commitment to innovation and scalability remains evident.
Opportunities lie in exploring combination therapies, addressing patient preferences, and leveraging market trends for future growth.
Overall, Viking's performance, strengths, and strategic outlook position them well for continued success in the biopharmaceutical sector.

Viking Therapeutics excels in clinical trials and financial growth

Viking Therapeutics showcased positive trial results, financial strength, and a proactive approach to advancing their pipeline. While facing challenges in managing expenses and navigating regulatory requirements, the company remains optimistic about the potential of their clinical programs. Opportunities for growth exist through successful trial outcomes, strategic partnerships, and regulatory engagements.

Viking Therapeutics reports strong Q1 results and plans pipeline expansion

Viking Therapeutics showcased positive clinical outcomes for VK2735 and VK2809, supported by a successful public offering.
Financially, the company reported increased expenses but maintains a robust cash position for future development.
Challenges include managing expenses, regulatory transitions, and data reporting timelines, while opportunities lie in market expansion and regulatory advancements.
Overall, Viking's strategic focus on pipeline advancement and leveraging strong financials positions them for continued growth and success.

Viking Therapeutics advances breakthrough therapies with strong financial backing

Viking Therapeutics reported positive trial outcomes and a strong financial position, poised to advance breakthrough therapies for obesity and NASH.
While facing regulatory and financial challenges, Viking's innovative approach and diverse pipeline present opportunities for growth and strategic partnerships.
With a focus on advancing Phase III programs and exploring new treatment avenues, Viking remains well-positioned to drive therapeutic innovation and address unmet medical needs.

Viking Therapeutics excels in clinical trials and strategic partnerships

Viking Therapeutics delivered strong clinical progress and financial stability in Q3 2024, positioning itself for further growth and development. While facing cost challenges, the company is actively pursuing strategic opportunities to advance its pipeline and expand its market presence.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Altimmune

Structure Therapeutics Inc

With global obesity numbers bursting at the seams, some of the smartest biotech stocks to buy are those with weight loss drugs. Just look at Eli Lilly (NYSE: LLY ).

The 3 Smartest Biotech Stocks to Buy With $5K Right Now

Eli Lilly

Novo Nordisk

Weight loss drugs have taken the pharmaceutical and medical communities by storm. Not only are the companies behind the medications struggling to keep up with global demand, but reports are emerging that the drugs could alleviate health problems beyond obesity.

The Top 3 Weight Loss Drug Stocks to Buy for Huge Gains

Transmedics Group Inc

Vertex Pharmaceuticals

Vertex Pharmaceuticals could have multiple new blockbusters on the way. Viking Therapeutics is targeting two massive markets -- obesity and NASH.

Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030

In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $47.39, denoting a -0.86% change from the preceding trading day.

Viking Therapeutics, Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to Know

Archer Aviation

Innovation stocks can be hidden gems. Archer Aviation and Viking Therapeutics are two intriguing innovators with a high ceiling.

Better Growth Stock: Archer Aviation or Viking Therapeutics?

Company's Receptor Co-Agonists Demonstrate Potent Body Weight Reductions, Decreased Food Intake and Improved Metabolic Profile in Healthy Rats and Diet-Induced Obese Mice SAN DIEGO , June 24, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the presentation of preclinical data from a series of internally developed dual agonists of the amylin and calcitonin receptors at the 84th Scientific Sessions of the American Diabetes Association.  The presentation highlights the effects of treatment on body weight, food intake and metabolic profile in healthy rats and diet-induced obese (DIO) mice as compared to control cohorts treated with vehicle or the dual amylin and calcitonin receptor agonist cagrilintide.

Viking Therapeutics Presents Preclinical Data on Novel Dual Amylin and Calcitonin Receptor Agonists at 84th Scientific Sessions of the American Diabetes Association

Super Micro Computer

Summit Therapeutics

These three stocks have soared between 179% and 220% so far this year. Wall Street thinks they can all jump at least 20% over the next 12 months.

3 Stocks That Have Soared 179% or More in 2024 and Could Go Even Higher, According to Wall Street

Riot Blockchain

Viking Therapeutics and Riot Platforms are two speculative investments analysts are bullish on. Viking doesn't have an approved product yet but VK2735 has been demonstrating encouraging results in clinical trials.

2 Growth Stocks Wall Street Analysts Think Can Soar by at Least 80%

Viking Therapeutics has the potential to be a great growth stock. The company, however, faces a lot of competition in the GLP-1 drug market.

Viking Therapeutics Is Great. Here's Why You Shouldn't Buy It

In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $52.10, denoting a -0.69% change from the preceding trading day.

Viking Therapeutics, Inc. (VKTX) Stock Declines While Market Improves: Some Information for Investors

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Wall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy?

Digital Realty Trust

One of the best ways to spot winning stocks to buy is by spotting hot trends. Just look at artificial intelligence, machine learning, biotech, obesity treatment and solar energy booms that still offer solid opportunities.

3 Stocks to Buy if You Want to Turn Your $1,000 into $10,000 Within 2 Years

Madrigal Pharmaceuticals

Madrigal Pharmaceuticals has a monopoly in its main market -- for the moment. Viking Therapeutics has a good candidate, but it could face powerful competitors.

Better Biotech Stock: Viking Therapeutics vs. Madrigal Pharmaceuticals

Viking Therapeutics just reported (more) positive phase 2 clinical trial results. Though the company's shares dropped, interested investors shouldn't worry.

This High-Flying Stock Just Announced More Good News: Time to Buy?

CrowdStrike

McDonald's

Many people are looking for stocks to buy, driven by just one thing: fear. Whether it is the fear of losing it all or the fear of missing out (FOMO), investors tend to run in packs.

Profiting from the Crowd: 3 Stocks Set to Surge on Retail Investor Enthusiasm

Viking Therapeutics, Inc. (VKTX) concluded the recent trading session at $55.99, signifying a +1.78% move from its prior day's close.

Viking Therapeutics, Inc. (VKTX) Advances While Market Declines: Some Information for Investors

Viking Therapeutics stock took a hit this week in response to a clinical update for its midstage liver disease drug. This pullback seems unwarranted, given the company's pivot to weight loss.

Is Viking Therapeutics Stock a Buy on the Dip?

Albertsons Companies

AGCO

Brandywine Realty

Deere & Company

FedEx

Harrow Health Inc

Humacyte

Aberdeen Standard Physical Platinum Shares ETF

Sibanye Stillwater

Texas Pacific Land Trust

Uniti Group

The "Undercovered" Dozen highlights twelve ideas from the previous month on stocks with limited coverage. Albertsons, Viking Therapeutics, Brandywine Realty Trust, platinum, and more are discussed in this edition. A number of veteran Seeking Alpha analysts are on display in this one. And one of them shares a thesis about their largest portfolio holding at 12%.

The 'Undercovered' Dozen From May 2024

Viking Therapeutics (VKTX) reports promising 52-week treatment data from a mid-stage study on its experimental NASH drug. However, shares drop as management did not provide any info on future plans.

Viking (VKTX) Falls 10% Despite Upbeat NASH Study Results

Viking Therapeutics Inc (NASDAQ: VKTX) is in focus today after announcing positive Phase 2b data for its treatment for biopsy-confirmed non-alcoholic steatohepatitis (NASH). $VKTX's drug did significantly better than placebo VK2809 of the biotech firm helped improve fibrosis and prevented worsening of NASH in 51% of the participants after 52-weeks of dosage.

Viking Therapeutics reports promising data for liver disease drug

Viking Therapeutics stock falls despite seemingly positive test results for a drug that treats a serious liver disease.

Viking Therapeutics Stock Crumbles Despite Potential 'Best-In-Class' Liver Disease Drug

Up to 75% of Patients Treated with VK2809 Achieved NASH Resolution with No Worsening of Fibrosis as Compared to 29% for Placebo (p=0.0001) Up to 57% of VK2809-Treated Patients Achieved ≥1-Stage Improvement in Fibrosis with No Worsening of NASH as Compared to 34% for Placebo (p

Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)

Recursion Pharmaceuticals

Biotechs that aspire to be disruptive are quite risky. However, they do offer the chance of disproportionate rewards.

1 Disruptive Biotech Stock to Buy Now, and 1 to Consider

Amgen

AstraZeneca

Eli Lilly and Novo Nordisk aren't the only ones making anti-obesity drugs. Amgen, AstraZeneca, and Viking Therapeutics have credible candidates.

The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.

The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $62.26, representing a +0.78% change from its previous close.

News for Viking Therapeutics Stock (VKTX)